Changelog — 2026-02-20
2026-02-20
MRK
Merck & Co., Inc.
Status: COMPLETED → TERMINATED (Study was closed early due to slow enrollment.) — PHASE2
NCT03990961
• Phase 2 • Status: Completed → Terminated • Why stopped: Study was closed early due to slow enrollment.
🚩 MAJOR
2026-02-20
C
CHCO
CITY HOLDING CO
Status: NOT_YET_RECRUITING → WITHDRAWN (withdrawn) — PHASE1
NCT07061574
• Phase 1 • Status: Not yet recruiting → Withdrawn • Why stopped: withdrawn
🚩 MAJOR
2026-02-20
O
ONON
On Holding AG
CT.gov status: ENROLLING_BY_INVITATION → SUSPENDED (Potential study redesign) — NA — investigator-sponsored (collaborator: ONON)
NCT06505993
• Na • Status: Enrolling by invitation → Suspended • Why stopped: Potential study redesign
HIGH
2026-02-20
C
CHCO
CITY HOLDING CO
Primary endpoint added: Total Perioperative Opioid Consumption — NA
NCT06808737
• Na
MEDIUM
2026-02-20
H
HLN
Haleon plc
Primary endpoint added: Mean Change From Baseline in Each of the WURSS-21 Symptom Scores: Cough — PHASE4
NCT06716645
• Phase 4
MEDIUM
2026-02-20
C
CRNX
Crinetics Pharmaceuticals, Inc.
Locations updated — PHASE3
NCT07087054
• Phase 3
MEDIUM
2026-02-20
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Locations updated — PHASE1
NCT06845202
• Phase 1
MEDIUM
2026-02-20
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Locations updated — PHASE2
NCT06393712
• Phase 2
MEDIUM
2026-02-20
H
HSY
HERSHEY CO
Enrollment 900→297 (-67%)
NCT06444542
• Enrollment 900→297 (-67%)
MEDIUM
2026-02-20
REGN
REGENERON PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT07015905
• Phase 3
MEDIUM
2026-02-20
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Locations updated — PHASE1
NCT07214727
• Phase 1
MEDIUM
2026-02-20
Z
ZLDPF
Zealand Pharma A/S/ADR
Status: NOT_YET_RECRUITING → RECRUITING — PHASE3
NCT07197944
• Phase 3 • Status: Not yet recruiting → Recruiting
MEDIUM
2026-02-20
U
UNTC
UNIT CORP
Enrollment 50000→117000 (134%) — NA
NCT05676541
• Na • Enrollment 50000→117000 (+134%)
MEDIUM
2026-02-20
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Locations updated — PHASE3
NCT06611163
• Phase 3
MEDIUM
2026-02-20
L
LXRX
LEXICON PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT06291376
• Phase 3
MEDIUM
2026-02-20
M
MIRM
Mirum Pharmaceuticals, Inc.
Locations updated — PHASE2
NCT07209462
• Phase 2
MEDIUM
2026-02-20
NVS
NOVARTIS AG
Enrollment 14082→14111 (0%) — PHASE3
NCT05739383
• Phase 3 • Enrollment 14082→14111 (+0%)
MEDIUM
2026-02-20
S
SO
SOUTHERN CO
Enrollment 160→140 (-12%) — NA
NCT06361914
• Na • Enrollment 160→140 (-12%)
MEDIUM
2026-02-20
U
UNTC
UNIT CORP
Enrollment 120→122 (2%) — PHASE1
NCT05385510
• Phase 1 • Enrollment 120→122 (+2%)
MEDIUM
2026-02-20
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Status: NOT_YET_RECRUITING → ACTIVE_NOT_RECRUITING — PHASE3
NCT07144852
• Phase 3 • Status: Not yet recruiting → Active, not recruiting
MEDIUM
2026-02-20
ALNY
ALNYLAM PHARMACEUTICALS, INC.
Locations updated — PHASE3
NCT07181109
• Phase 3
MEDIUM
2026-02-20
O
ONON
On Holding AG
Primary endpoint added: Evaluate Uptake of Pre-exposure Prophylaxis (PrEP) — NA
NCT06187064
• Na
MEDIUM
2026-02-20
REGN
REGENERON PHARMACEUTICALS, INC.
Locations updated — PHASE2
NCT07175428
• Phase 2
MEDIUM
2026-02-20
TEVA
TEVA PHARMACEUTICAL INDUSTRIES LTD
Locations updated — PHASE3
NCT07144852
• Phase 3
MEDIUM
2026-02-20
C
CRNX
Crinetics Pharmaceuticals, Inc.
Locations updated — PHASE2
NCT07159841
• Phase 2
MEDIUM
2026-02-20
O
ONON
On Holding AG
Primary endpoint added: Number and Percentage of Participants With Documented Current Use of MOUD at Week 26 by Site — NA
NCT04804072
• Na
MEDIUM
2026-02-20
C
CHCO
CITY HOLDING CO
Enrollment 120→0 (-100%) — PHASE1
NCT07061574
• Phase 1 • Enrollment 120→0 (-100%)
MEDIUM
2026-02-20
NVS
NOVARTIS AG
Enrollment 432→443 (3%) — PHASE2
NCT06780670
• Phase 2 • Enrollment 432→443 (+3%)
MEDIUM
2026-02-20
R
RLAY
Relay Therapeutics, Inc.
Enrollment 18→10 (-44%) — PHASE1
NCT06460844
• Phase 1 • Enrollment 18→10 (-44%)
MEDIUM
2026-02-20
C
CTMX
CytomX Therapeutics, Inc.
Enrollment 124→160 (29%) — PHASE1
NCT06265688
• Phase 1 • Enrollment 124→160 (+29%)
MEDIUM